Moderate, severe, critical and fatal groups of COVID-19 participants showed higher levels of antibody anti-SARS-CoV-2 proteins in comparison to controls (Figure 1), except for anti-NP IgM (control vs. moderate, p=0.1236) (Figure 1C). This evidence concerns the gene CD40LG and COVID-19.